Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BYVaccines

Group A Streptococcus-Attributable Mortality and Disability in Asian Adults Aged 60 Years and Older: Global Burden of Disease Study 2023 and Projections to 2050

  1. 1Department of Otolaryngology Head and Neck Surgery, Yangzhou University Affiliated Hospital, Yangzhou 225001, China
  2. 2Department of Otolaryngology Head and Neck Surgery, Zhenjiang First People’s Hospital, Zhenjiang 212002, China

Abstract

Background: Group A Streptococcus (GAS) remains a leading cause of preventable mortality and disability among older adults, yet its long-term epidemiological trajectory in Asia’s rapidly ageing populations remains poorly characterised. Methods: Data on GAS-attributable deaths and disability-adjusted life years (DALYs) among adults aged 60 years and older were extracted from the Global Burden of Disease Study 2023 (rei_id 630, all causes [cause_id 294]; within which the attributable burden at ages ≥60 is carried by lower respiratory infections [cause_id 322]) for 34 Asian countries from 1990 to 2023, aggregated into five GBD-defined subregions. Temporal trends were assessed using Joinpoint regression, and future burdens from 2024 to 2050 were projected using a Bayesian age-period-cohort (BAPC) model with retrospective validation and sensitivity analysis. Estimates are reported as age-standardised rates per 100,000 population with 95% uncertainty or prediction intervals. Results: In 2023, the highest age-standardised death rates were observed in Singapore (3.31 per 100,000 [95% UI, 2.61–3.91]), Lao PDR (3.19 [95% UI, 2.20–4.49]), and Taiwan (2.89 [95% UI, 2.47–3.32]), whereas the lowest were in Kyrgyzstan (0.15 [95% UI, 0.13–0.18]) and Turkmenistan (0.19 [95% UI, 0.16–0.22]). From 1990 to 2023, age-standardised death rates increased most markedly in Central Asia (average annual percentage change [AAPC], 3.63% [95% CI, 3.41–3.85%]) and Southeast Asia (AAPC, 3.09% [95% CI, 2.87–3.31%]), while East Asia showed minimal change (AAPC, 0.06% [95% CI, −0.04% to 0.16%]); East Asia was the only subregion with declining DALY rates (AAPC, −0.82% [95% CI, −0.93% to −0.71%]). Males experienced higher death rates than females in all subregions except South Asia (male-to-female ratio 0.98–1.96). Decomposition showed that years lived with disability contribute 0.07–0.90% of GAS-attributable DALYs, indicating that the burden is overwhelmingly mortality-driven. BAPC projections to 2050 indicate a divergent future: death rates in Central Asia are projected to show the largest relative increase, from 0.53 to a median of 2.46 per 100,000 by 2050 (95% PI, 0.93–6.43; +364%), albeit with substantial uncertainty and with retrospective validation indicating that prediction intervals may be underestimated in this subregion; High-income Asia Pacific is projected to retain the highest absolute burden (2.10 to 2.77 per 100,000 [95% PI, 1.18–6.37]); Southeast Asia (0.98 to 1.13 per 100,000 [95% PI, 0.40–3.16]), East Asia (0.40 to 0.49 per 100,000 [95% PI, 0.18–1.41]) and South Asia (0.55 to 0.39 per 100,000 [95% PI, 0.11–1.30]) are projected to change modestly. For DALYs, Central Asia is projected to experience the largest increase (9.78 to a median of 43.49 per 100,000 [95% PI, 15.68–129.46] by 2050), followed by High-income Asia Pacific (24.98 to 28.55 per 100,000 [95% PI, 12.39–68.01]). Conclusions: Asia’s ageing populations face divergent GAS-attributable health burdens. Central Asia is projected to face the largest relative increase in mortality and DALYs by 2050, accompanied by substantial, possibly under-quantified uncertainty, while High-income Asia Pacific carries the highest absolute burden throughout the projection period. These findings underscore the need for targeted prevention strategies, including GAS vaccine development, with particular attention to Central Asia and other rapidly changing subregions of Asia.

Related

  1. Escalating Burden of Osteoarthritis Among Asian Women: Regional Trends, BMI-Attributable Disability, and Projections to 2050
    Wenjing Zhang, Haoran Peng, Li Li +1
    International Journal of Women's HealthPeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC
  2. Tobacco-attributable burden of alzheimer’s disease and other dementias in China and ASEAN : Temporal trends and projections – an observational study based on GBD 2021
    Piaoyun Wen, Wenwen Liu, Yanjiang Li +12
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Global burden of chronic kidney disease attributable to hypertension due to high body mass index: projections to 2050.
    Luohua Li, Guoqiang Zhu, Ke-Ke Wang +3
    Renal failurePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  4. Tobacco-attributable mortality and disease burden in India: a descriptive analysis of Global Burden of Disease 2023 estimates for 1990 and 2023
    Chaitali Mandal, Mayank Singh, Murali Dhar
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textPhysiologyCrossref
  5. Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023
    Marco Zuin, Claudio Bilato, Gianluca Rigatelli +2
    Journal of the American Heart AssociationPeer-reviewedCC BY-NC-NDCardiovascular medicineCrossref
BibTeX
@article{wang2026group,
  title = {{Group A Streptococcus-Attributable Mortality and Disability in Asian Adults Aged 60 Years and Older: Global Burden of Disease Study 2023 and Projections to 2050}},
  author = {Min Wang and Juebo Yu},
  journal = {Vaccines},
  year = {2026},
  month = oct,
  doi = {10.3390/vaccines14100880},
  url = {https://europepmc.org/article/PMC/PMC13709945},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Group A Streptococcus-Attributable Mortality and Disability in Asian Adults Aged 60 Years and Older: Global Burden of Disease Study 2023 and Projections to 2050
AU  - Min Wang
AU  - Juebo Yu
PY  - 2026
DA  - 2026/10/01
JO  - Vaccines
DO  - 10.3390/vaccines14100880
UR  - https://europepmc.org/article/PMC/PMC13709945
AB  - Background: Group A Streptococcus (GAS) remains a leading cause of preventable mortality and disability among older adults, yet its long-term epidemiological trajectory in Asia’s rapidly ageing populations remains poorly characterised. Methods: Data on GAS-attributable deaths and disability-adjusted life years (DALYs) among adults aged 60 years and older were extracted from the Global Burden of Disease Study 2023 (rei_id 630, all causes [cause_id 294]; within which the attributable burden at ages ≥60 is carried by lower respiratory infections [cause_id 322]) for 34 Asian countries from 1990 to 2023, aggregated into five GBD-defined subregions. Temporal trends were assessed using Joinpoint regression, and future burdens from 2024 to 2050 were projected using a Bayesian age-period-cohort (BAPC) model with retrospective validation and sensitivity analysis. Estimates are reported as age-standardised rates per 100,000 population with 95% uncertainty or prediction intervals. Results: In 2023, the highest age-standardised death rates were observed in Singapore (3.31 per 100,000 [95% UI, 2.61–3.91]), Lao PDR (3.19 [95% UI, 2.20–4.49]), and Taiwan (2.89 [95% UI, 2.47–3.32]), whereas the lowest were in Kyrgyzstan (0.15 [95% UI, 0.13–0.18]) and Turkmenistan (0.19 [95% UI, 0.16–0.22]). From 1990 to 2023, age-standardised death rates increased most markedly in Central Asia (average annual percentage change [AAPC], 3.63% [95% CI, 3.41–3.85%]) and Southeast Asia (AAPC, 3.09% [95% CI, 2.87–3.31%]), while East Asia showed minimal change (AAPC, 0.06% [95% CI, −0.04% to 0.16%]); East Asia was the only subregion with declining DALY rates (AAPC, −0.82% [95% CI, −0.93% to −0.71%]). Males experienced higher death rates than females in all subregions except South Asia (male-to-female ratio 0.98–1.96). Decomposition showed that years lived with disability contribute 0.07–0.90% of GAS-attributable DALYs, indicating that the burden is overwhelmingly mortality-driven. BAPC projections to 2050 indicate a divergent future: death rates in Central Asia are projected to show the largest relative increase, from 0.53 to a median of 2.46 per 100,000 by 2050 (95% PI, 0.93–6.43; +364%), albeit with substantial uncertainty and with retrospective validation indicating that prediction intervals may be underestimated in this subregion; High-income Asia Pacific is projected to retain the highest absolute burden (2.10 to 2.77 per 100,000 [95% PI, 1.18–6.37]); Southeast Asia (0.98 to 1.13 per 100,000 [95% PI, 0.40–3.16]), East Asia (0.40 to 0.49 per 100,000 [95% PI, 0.18–1.41]) and South Asia (0.55 to 0.39 per 100,000 [95% PI, 0.11–1.30]) are projected to change modestly. For DALYs, Central Asia is projected to experience the largest increase (9.78 to a median of 43.49 per 100,000 [95% PI, 15.68–129.46] by 2050), followed by High-income Asia Pacific (24.98 to 28.55 per 100,000 [95% PI, 12.39–68.01]). Conclusions: Asia’s ageing populations face divergent GAS-attributable health burdens. Central Asia is projected to face the largest relative increase in mortality and DALYs by 2050, accompanied by substantial, possibly under-quantified uncertainty, while High-income Asia Pacific carries the highest absolute burden throughout the projection period. These findings underscore the need for targeted prevention strategies, including GAS vaccine development, with particular attention to Central Asia and other rapidly changing subregions of Asia.
SN  - 2076-393X
ER  -